SIGNUM BIOSCIENCES, INC. — Department of Health and Human Services SBIR Phase II: NIAID
SIGNUM BIOSCIENCES, INC. — SBIR Phase II award from Department of Health and Human Services.
- Amount
- $2,964,464
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase II
- Topic
- NIAID
- Solicitation
- PA16-302
- NAICS
- —
- Place of performance
- NJ
- Period
- 2017-02-14 → 2021-01-31
Description
SUMMARY Atopic dermatitis is a chronic dermatological condition afflicting mostly infants and young childrenCurrent treatments are associated with a wide range of side effects therefore development of novel therapeutic agents that are efficacious and have an improved safety profile is neededAlthough disease etiology has yet to be fully understoodskin inflammation is known to be critically involved in the disease pathologySignum has identified two novel potent topical anti inflammatory agentslead compoundSIGbackup compoundSIGcalled isoprenylcysteinesIPCswith no detectable adverse affectsThe proposed Phase IIB research plan will enable the filing of an investigational new drugINDapplication for the first in human trials in ADIn addition this grant proposal will buttress Post IND clinical efforts by completing additional juvenile safety and continue drug substance and drug product development for Phase II clinical trials NARRATIVE Atopic dermatitis is a chronic pruritic skin disorder afflicting mainly children under the age of fiveCurrent treatmentsalthough efficacious in reducing symptoms are associated with adverse effectsSuccessful pharmaceutical development of topical IPC analog anti inflammatories will provide an important additionaland potentially bettertherapeutic option for people suffering from atopic dermatitis